Subject
U.S. Gov't; PedPal Lit; Non-U.S. Gov't Research Support; 15 patients had stable disease; 2 (n=3); 2 (n=9); 22 (n=1 patient); 3 (n=1); 4 (n=2(TRUNCATED); 4 (n=6); 7 (n=1 patient); 7 were not evaluable for response because of concurrent radiotherapy; Adolescent Adult Antineoplastic Agents; although they did not have progressive disease (PD) after receiving 1 (n=10); and 1 patient had a major response. Twenty-one patients had PD after 1 (n=3; and myelosuppressive effects were readily managed. Hospitalizations were limited to three patients with bacteremia. Twenty-three patients had a change in therapy; diarrheal; Intravenous Male Nervous System Neoplasms/drug therapy Neuroblastoma/drug therapyPalliative Care Quality of Life Research Support; or 24 (n=1) courses. The most common reasons for changing treatment were to intensify retrieval therapy or to pursue immunotherapy. Of those 23 patients; P.H.S. Retrospective Studies Treatment Outcome; Phytogenic/administration & dosage/adverse effects Camptothecin/administration & dosage/adverse effects/analogs & derivatives Child Child; Preschool Female Humans Infusions